In the effort to maintain the activity of BIM, many studies on cancer therapies using “BH3 mimics” that bind to this domain of BCL-2 family proteins have been reported (Souers et al. 2013; Wang et al. 2016; Konopleva et al. 2016; Campos and Pinto 2019; Fleischmann et al. 2022; Calis et al. 2022). This evidence concerns the gene BCL2 and cancer.